MedicalResearch.com Interview with:
Nitesh D. Kuhadiya MD, MPH
Assistant Professor of Medicine
Section of Endocrinology,Diabetes and Metabolism
University of Buffalo, New York
MedicalResearch: What are the main findings of the study?
Dr. Kuhadiya: This is the first randomized clinical trial to show that the addition of liraglutide 1.2 and 1.8mg to insulin significantly reduces HbA1c, mean blood glucose, total insulin doses, body weight, carbohydrate intake, C-Reactive protein (a marker of cardiovascular risk), significantly improves quality of life and reduces systolic blood pressure(top number in a blood pressure reading) in 1.8mg group in patients with type 1 diabetes over a period of 12 weeks.
In 1.2mg, HbA1c fell by 0.78% from 7.84 to 7.06% and in 1.8mg group fell by 0.42% from 7.41 to 6.99% which means that more number of patients will be able to achieve HbA1c levels close to 7% and lower which is recommended by most diabetes organizations. Also the total daily dose of
insulin fell by about 10-12 units in both groups. The total daily carbohydrate intake in both the groups fell by an average of 40 grams. There was a 5 kg weight loss in both 1.2 mg and 1.8 mg groups and both these groups on an average lowered their Body Mass Index from 29 to 28 kg/m
2 . In 1.8 mg group there was fall in systolic blood pressure by 9 mm from 120 to 111 mm Hg.
The improvements seen are important because 40 to 50 percent of people with Type 1 diabetes have the metabolic syndrome(Cluster of risk factors, including high blood pressure, large waistline, high blood sugar, low HDL ("good") cholesterol and high triglycerides (fats in the blood) which increases the chances of later developing Type 2 diabetes and heart disease.
Our findings have significant implications for the future treatment of patients with Type 1 Diabetes.
(more…)